Investigational drug · Phase 3
Bomedemstat
Also called: MK-3543, IMG-7289
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
17
Any phase or sponsor naming "Bomedemstat"
First trial start
2023
Sep 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bomedemstat", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Polycythemia Vera
- Essential Thrombocythemia
- Thrombocythemia, Essential
- Primary Myelofibrosis
- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Bomedemstat" as an intervention, largest first.
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06351631 · 400 participants (planned) · Start May 23, 2024 · Primary completion Dec 4, 2034
Drug: Bomedemstat · For: Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis and 3 more
Sites: Ann Arbor, Michigan; Durham, North Carolina; Columbus, Ohio · 21 sites in all
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07722611 · 380 participants (planned) · Start Oct 29, 2026 · Primary completion Jun 25, 2032
Drug: Bomedemstat; Ruxolitinib and 1 more · For: Polycythemia Vera
Sites: Newark, Delaware; Columbia, Maryland; Eugene, Oregon · 8 sites in all
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06079879 · 340 participants (planned) · Start Dec 31, 2023 · Primary completion Jul 14, 2027
Drug: Bomedemstat; Anagrelide and 3 more · For: Essential Thrombocythemia
Sites: Glendale, Arizona; Glendale, California; Stanford, California · 161 sites in all
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06456346 · 300 participants (planned) · Start Jul 16, 2024 · Primary completion Sep 28, 2027
Drug: Bomedemstat; Hydroxyurea and 2 more · For: Essential Thrombocythemia
Sites: Glendale, Arizona; Glendale, California; Palo Alto, California · 171 sites in all
- Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)Completed
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
NCT03136185 · 90 participants · Start Jul 18, 2017 · Primary completion Mar 8, 2022
Drug: Bomedemstat · For: Myelofibrosis; Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF) and 1 more
Sites: Ann Arbor, Michigan; Adelaide, Australia; Essen, Germany · 5 sites in all
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
NCT05223920 · 81 participants · Start Dec 15, 2021 · Primary completion Aug 22, 2024
Drug: Bomedemstat · For: Thrombocythemia, Essential; Primary Myelofibrosis
Sites: Miami, Florida; Ann Arbor, Michigan; Cleveland, Ohio · 19 sites in all
- Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)Completed
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
NCT04254978 · 73 participants · Start Sep 8, 2020 · Primary completion Mar 23, 2023
Drug: Bomedemstat · For: Essential Thrombocythemia
Sites: Jacksonville, Florida; Ann Arbor, Michigan; New York, New York · 26 sites in all
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)Industry
NCT02842827 · 45 participants · Start Oct 6, 2016 · Primary completion Oct 30, 2018
Drug: bomedemstat; tretinoin · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Sites: Adelaide, Australia
- Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisNot yet recruiting
United Lincolnshire Hospitals NHS TrustAcademic, hospital or other
NCT07424950 · 40 participants (planned) · Start Nov 1, 2026 · Primary completion Nov 1, 2028
Drug: bomedemstat · For: Myelofibrosis
The University of Hong KongAcademic, hospital or other
NCT05569538 · 40 participants (planned) · Start Dec 1, 2022 · Primary completion Dec 31, 2024
Drug: Bomedemstat · For: Myelofibrosis
Sites: Hong Kong, Hong Kong
Newest research
PubMed records naming it or its code names, newest first.
- Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing.
Sookhaklari M, Moinuddin A, Singh K, et al. · J Immunother 2026
- The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
Gill H, Yacoub A, Gerds AT, et al. · Blood Adv 2026
- Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia.
Gill H, Palandri F, Ross DM, et al. · Blood Adv 2026
- Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
Aluri A, Kishtagari A · Semin Hematol 2026
- Therapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies.
Khan SA, Qamar MA, Feroze MT · Ann Med Surg (Lond) 2026
- Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma.
Stitzlein LM, Nam D, Hernandez FA, et al. · Neurooncol Adv 2025
Also in development for Polycythemia Vera
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- SapablursenISIS 702843, ONO-0530Phase 32 trials
Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera
- AG-236Phase 31 trial
Agios Pharmaceuticals, Inc. · Polycythemia Vera
- JBI-802Phase 21 trial
Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera
- SLN124Phase 21 trial
Silence Therapeutics plc · Polycythemia Vera
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.